C-CAR168
Phase 2Biologic
C-CAR168 is one of 36 biologic programs targeting Multiple Sclerosis. It is currently in Phase 2.
3
Indications
4
Total Trials
3
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
138 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Clemastine Fumarate
NovartisPhase 3
Activated Charcoal
SanofiPhase 3
Recombinant Zoster Vaccine
MMAXVAX Biotechnology Limited Liability Company
Phase 3
MRI Contrast-Enhancing Agents
SanofiPhase 3
Frexalimab
SanofiPhase 3
Tolebrutinib
SanofiPhase 3
PBR06
UUniversity Hospital, Bordeaux
Phase 3
Flomax
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lupus Nephritis (LN)2 trials
Systemic Sclerosis (SSc)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for C-CAR168. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- AAbelZeta Inc.